EyePoint Pharmaceuticals
480 Pleasant Street
Suite B300
Watertown
Massachusetts
02472
United States
Website: http://www.eyepointpharma.com/
About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals, Inc. is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve the lives of patients with serious eye disorders.
160 articles about EyePoint Pharmaceuticals
-
EyePoint Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Developments
11/1/2023
EyePoint Pharmaceuticals, Inc. announced financial results for the third quarter ended September 30, 2023, and highlighted recent corporate developments.
-
EyePoint Pharmaceuticals to Host Virtual Key Opinion Leader (KOL) Event on November 9, 2023
10/31/2023
EyePoint Pharmaceuticals, Inc., a company committed to developing and commercializing therapeutics to improve the lives of patients with retinal diseases, announced it will host a virtual key opinion leader event on Thursday, November 9, 2023 from 8:00 to 9:00 am ET.
-
EyePoint Pharmaceuticals Announces Presentations at Eyecelerator 2023, American Academy of Ophthalmology Annual Meeting 2023 and Guggenheim’s 5th Annual Inflammation, Neurology & Immunology Conference 2023
10/30/2023
EyePoint Pharmaceuticals, Inc. announced that the Company will present at upcoming medical meetings and an investor conference.
-
EyePoint Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 1, 2023
10/25/2023
EyePoint Pharmaceuticals, Inc. today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 1, 2023 to report its third quarter 2023 financial results and highlight recent corporate developments.
-
EyePoint Pharmaceuticals Strengthens Board and Executive Leadership Team
10/16/2023
EyePoint Pharmaceuticals, Inc. announced the appointment of Stuart Duty to its Board of Directors and the promotion of George Elston to Executive Vice President.
-
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - September 18, 2023
9/18/2023
EyePoint Pharmaceuticals, Inc. announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635.
-
EyePoint Pharmaceuticals Reports Positive Masked Safety Update for Lead Product Candidate EYP-1901 in Ongoing PAVIA and DAVIO 2 Phase 2 Clinical Trials as of September 1, 2023
9/11/2023
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) today announced positive interim masked safety data for its lead product candidate EYP-1901 from the Company’s ongoing Phase 2 PAVIA trial evaluating EYP-1901 as a potential nine-month treatment for moderately-severe to severe non-proliferative diabetic retinopathy (NPDR) and DAVIO 2 trial as a potential six-month sustained delivery maintenance treatment for wet age-related macular degeneration (wet AMD).
-
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences - August 30, 2023
8/30/2023
EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, announced that the Company will participate at the following upcoming conferences.
-
EyePoint Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
8/9/2023
EyePoint Pharmaceuticals, Inc. today announced that Jay S. Duker, M.D., President and Chief Executive of EyePoint Pharmaceuticals will present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference.
-
EyePoint Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Corporate Developments
8/2/2023
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced financial results for the second quarter ended June 30, 2023 and highlighted recent corporate developments.
-
EyePoint Pharmaceuticals Presents Interim Masked Safety Data and Patient Baseline Characteristics for DAVIO 2 Clinical Trial at OIS Retina Innovation Summit
7/27/2023
EyePoint Pharmaceuticals today announced interim masked safety data and baseline patient demographics from its Phase 2 DAVIO 2 clinical trial of EYP-1901, a potential sustained delivery maintenance treatment for wet age-related macular degeneration (wet AMD).
-
EyePoint Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 2, 2023
7/26/2023
EyePoint Pharmaceuticals, Inc. today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, August 2, 2023 to report its second quarter 2023 financial results and highlight recent corporate developments.
-
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - July 17, 2023
7/17/2023
EyePoint Pharmaceuticals, Inc. today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
-
EyePoint Pharmaceuticals Announces Chief Executive Officer Transition
7/10/2023
EyePoint Pharmaceuticals, Inc. today announced the appointment of Jay S. Duker, M.D. as Chief Executive Officer (CEO).
-
EyePoint Pharmaceuticals Completes Enrollment in Phase 2 PAVIA Clinical Trial of EYP-1901 in Non-Proliferative Diabetic Retinopathy
6/5/2023
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) today announced it has completed enrollment in the Phase 2 PAVIA clinical trial evaluating EYP-1901 as a potential nine-month treatment for moderate to severe non-proliferative diabetic retinopathy (NPDR).
-
EyePoint Pharmaceuticals to Present at the 2023 Jefferies Healthcare Conference
5/31/2023
EyePoint Pharmaceuticals, Inc. announced that George Elston, Chief Financial Officer of EyePoint Pharmaceuticals, will present a company overview at the Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 2:30 p.m. ET.
-
EyePoint Pharmaceuticals Announces Sale of YUTIQ® to Alimera Sciences, Inc. for $82.5 Million Cash Plus Royalties
5/18/2023
EyePoint Pharmaceuticals, Inc. today announced that it has entered into a definitive agreement for the sale of YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18mg to Alimera Sciences, Inc. (“Alimera”).
-
Alimera Acquires U.S. Commercial Rights to YUTIQ®
5/18/2023
Alimera Sciences, Inc. today announced its acquisition of additional commercialization rights for YUTIQ (fluocinolone acetonide intravitreal insert) 0.18mg for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye from EyePoint Pharmaceuticals, Inc. (EyePoint).
-
EyePoint Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Developments
5/3/2023
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced financial results for the first quarter ended March 31, 2023 and highlighted recent corporate developments.
-
EyePoint Pharmaceuticals to Report First Quarter 2023 Financial Results on May 3, 2023
4/26/2023
EyePoint Pharmaceuticals, Inc. today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 3, 2023 to report its first quarter 2023 financial results and highlight recent corporate developments.